1,609 views 1 year ago
    Echosens is a high-tech Limited Liability Corporation (société anonyme) incorporated under the law of France on 20 June 2001.

    Echosens is the world’s leading provider of non-invasive medical devices dedicated to the assessment of chronic liver diseases. There were over 700 million cases of chronic liver diseases in Europe, the PRC and the United States by the end of 2015. Our products and solutions support physicians in their assessment of patients with various types of chronic liver diseases, including diseases caused by virus, such as HBV and HCV, and diseases caused by alcohol abuse or obesity, such as AFLD, NAFLD, NASH and ASH.

    This film is for informational purposes only and is being made available solely on a confidential basis and subject to the following restrictions to a limited number of persons. It is issued for the exclusive use of the persons to whom it is addressed. By attending this presentation, you are agreeing to maintain confidentiality regarding the information disclosed herein and to be bound by the limitations described herein.
    This film does not constitute or form part of any offer, solicitation or advertisement with respect to the sale or purchase of the securities or of any of the assets or businesses described herein and no part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. The distribution of this film may be restricted by law, and persons into whose possession this film comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
    This film contains certain forward-looking statements. Forward-looking statements are statements concerning future circumstances and results, and any other statements that are not historical facts. The forward-looking statements, including those cited from third party sources, contained in this film are based on numerous assumptions that may prove to be incorrect, and accordingly, actual results may vary. This film contains information and data relating to the industry in which the Company operates, which the Company has derived from third party sources without independent verification. The Company cannot ensure that these sources have compiled such information and data on the same basis or with the same degree of accuracy or completeness as are found in other industries, and you are cautioned not to place undue reliance on such information and data.
    No representation or warranty (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein and, accordingly, none of the Company, nor any of their respective affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers accepts any liability (in negligence or otherwise) whatsoever arising directly or indirectly from the use of this film.
    This film speaks as of its date unless stated otherwise in the film and the Company, does not undertake to update or otherwise revise this document or any other materials supplied. Neither the delivery of this film nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. Show less
    Read more
  • Echosens Webinar Play all

    Echosens Webinar dedicated to Clinical usefulness of FibroScan® and FibroMeter™ .
    This item has been hidden
  • VCTE™ Play all

    VCTE™ is a proprietary elastography technology developed by Echosens. VCTE™ allows for measurement of tissue elasticity with quantitative, reproducible, real time results expressed in kPa (kiloPascal) and is a standard recognized by hepatologists and validated by a large number of publications
    This item has been hidden
  • CAP™ Play all

    A tool for non invasive assessment and quantification of steatosis. CAP™ or the Controlled Attenuation Parameter is used to quantify liver steatosis. This new technique is coupled with the FibroScan® and measures ultrasound wave attenuation, which change depending mainly the viscosity of the medium through which the waves travel.
    • CAP™ - Véronique Miette - Duration: 4 minutes, 30 seconds.

      • 6 years ago
      Interview of Véronique Miette, PhD, Research Director, Echosens
      A novel non invasive physical quantitative parameter : CAP™ (Controlled Attenuation Parameter).
      MIETTE2012- Revision date 24/05/2012 ...
    • CAP™ - Pr Beaugrand - Duration: 5 minutes, 12 seconds.

      • 6 years ago
      Interview of Pr Beaugrand
      Sasso M. et al, Novel controlled attenuation parameter (CAP) for non-invasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C., in Press in Jou...
    • CAP™ - Pr De Ledinghen - Duration: 4 minutes, 20 seconds.

      • 5 years ago
      Interview of Prof. Victor De Ledinghen
      Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. De Ledinghen V., Vergniol J., Foucher J., M...
    • CAP™ - Dr. Thomas Karlas - Duration: 6 minutes, 40 seconds.

      • 7 months ago
      Interview of Docteur Thomas Karlas, M.D. Division of Gastroenterology and Rheumatology. University Hospital Leipzig. Leipzig, Germany. Individual patient meta-analysis of CAP™ for determining steat...
    This item has been hidden
  • Uploads Play all

    This item has been hidden
  • This item has been hidden
to add this to Watch Later

Add to

Loading playlists...